Prostate cancer is an insidious disease. In Vietnam, these patients only seek medical care when the disease already progresses to metastatic stages, and Androgen deprivation remains the mainstay of therapy. We like to share our findings with hormonal therapy for prostate cancer patients who are not indicated for prostatectomy at our hospital.

Prospectively reviewed cases of prostate cancer patients without surgical indications, who have been treated with hormonal therapy between July 2016 and September 2022 at Nguyen Tri Phuong Hospital.

A total of 57 patients (mean age 74.75 ± 9.9 years old) were included in this study. Within this cohort, there were 5 cases exhibited localized disease, 31 cases with locally advanced disease and 21 cases with metastatic manifestations. PSA level (>10 ng/ml) were reported in 44 cases (77.2%) and 32 cases (56.1%) with Gleason scores ≥ 8. The longest follow-up was 103 months. At the 18 months post- Androgen Deprivation Therapy (ADT), 5 patients still experienced bone pain and 1 with hematuria manifestation. The percentage of patients achieving “nadir” PSA at the 6, 12 and 18 months were 33.3%, 42.1% and 10.5% respectively. The 18-month survival rate was 89.5%. In regards to prostate cancer specific mortality, there were 3 cases due to acute myocardial infarction and 3 cases related to Covid complications.

Hormonal therapy should be the first choice for prostate cancer patients without surgical indications.